See more : GreenFirst Forest Products Inc. (ICLTF) Income Statement Analysis – Financial Results
Complete financial analysis of Syncom Formulations (India) Limited (SYNCOMF.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Syncom Formulations (India) Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Expensify, Inc. (EXFY) Income Statement Analysis – Financial Results
- InnoCare Optoelectronics Corporation (6861.TW) Income Statement Analysis – Financial Results
- Concordia Financial Group, Ltd. (7186.T) Income Statement Analysis – Financial Results
- Information Creative Co., Ltd. (4769.T) Income Statement Analysis – Financial Results
- COIMA RES S.p.A. SIIQ (CRES.MI) Income Statement Analysis – Financial Results
Syncom Formulations (India) Limited (SYNCOMF.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.syncomformulations.com
About Syncom Formulations (India) Limited
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It offers various products, including generics, alpha adrenoceptor agonists, analgesics, antipyretics, anti-inflammatory, anti-ulcer agents, antibiotics, antidepressants, antifungals, antihistamines, antimalarial, antiplatelet agents, antiprotozoal, antivirals, bronchodilators, calcium antagonists, cardiac medicines, central nervous stimulants, cephelo sporins, cortico steroids, estrogen, cough suppressants, erectile dysfunction, and electrolite. The company also provides histamines, homeostatic, hypoglycemic, hypolipidaemics, local anesthetics, multivitamins and nutritional supplements, sedative anticonvulsants, stimulants, and sympathomimetic products, as well as products used in the treatment of gout. In addition, it engages in the trading of commodities and renting of properties. Further, the company exports its products. It offers its pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquids orals, liquid vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and herbals. Syncom Formulations (India) Limited was founded in 1985 and is based in Indore, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.59B | 2.24B | 2.18B | 2.39B | 2.00B | 1.82B | 1.54B | 1.85B | 1.84B | 1.73B | 1.51B | 1.15B | 1.18B | 763.24M | 854.06M | 575.64M | 678.44M | 576.33M |
| Cost of Revenue | 2.03B | 1.42B | 1.47B | 1.67B | 1.57B | 1.41B | 1.14B | 1.32B | 1.36B | 1.16B | 1.05B | 775.38M | 1.00B | 733.73M | 761.91M | 508.40M | 610.96M | 527.92M |
| Gross Profit | 559.50M | 825.58M | 709.74M | 722.43M | 428.27M | 408.79M | 403.78M | 524.22M | 478.22M | 574.01M | 462.85M | 374.11M | 181.32M | 29.51M | 92.15M | 67.24M | 67.47M | 48.41M |
| Gross Profit Ratio | 21.58% | 36.81% | 32.58% | 30.19% | 21.40% | 22.46% | 26.22% | 28.36% | 26.00% | 33.10% | 30.59% | 32.55% | 15.31% | 3.87% | 10.79% | 11.68% | 9.95% | 8.40% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 22.01M | 26.24M | 18.86M | 14.17M | 13.04M | 13.31M | 70.12M | 197.28M | 4.60M | 138.03M | 10.97M | 5.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 272.56M | 233.16M | 263.99M | 169.01M | 118.68M | 147.07M | 88.44M | 14.86M | 89.02M | 29.76M | 118.28M | 74.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.78M |
| SG&A | 294.56M | 259.40M | 282.85M | 183.18M | 131.72M | 160.38M | 158.56M | 212.15M | 93.62M | 167.79M | 118.28M | 242.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.78M |
| Other Expenses | 0.00 | 146.00M | 36.61M | 37.85M | 43.95M | 43.33M | 35.82M | 21.92M | 9.44M | 5.02M | 4.46M | 3.87M | 122.54M | 20.01M | 18.28M | 6.47M | 7.29M | -25.20M |
| Operating Expenses | 345.63M | 674.68M | 536.99M | 373.24M | 301.81M | 330.39M | 324.04M | 390.44M | 341.51M | 426.73M | 331.19M | 296.31M | 122.54M | 20.01M | 18.28M | 6.47M | 7.29M | -21.42M |
| Cost & Expenses | 2.38B | 2.09B | 2.01B | 2.04B | 1.87B | 1.74B | 1.46B | 1.71B | 1.70B | 1.59B | 1.38B | 1.07B | 1.13B | 753.74M | 780.18M | 514.87M | 618.25M | 506.50M |
| Interest Income | 51.45M | 47.24M | 39.32M | 13.50M | 8.26M | 7.34M | 7.51M | 5.98M | 17.23M | 14.75M | 6.73M | 7.12M | 0.00 | 1.02M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 43.56M | 31.31M | 12.56M | 1.93M | 4.60M | 2.19M | 2.66M | 2.82M | 708.56K | 2.13M | 3.17M | 2.82M | 4.17M | 5.02M | 5.47M | 5.32M | 1.83M | 584.30K |
| Depreciation & Amortization | 47.22M | 45.39M | 39.48M | 40.35M | 40.61M | 40.03M | 37.30M | 31.23M | 29.98M | 34.32M | 30.73M | 29.10M | 27.16M | 23.64M | 21.74M | 14.01M | 17.81M | 14.70M |
| EBITDA | 430.28M | 341.47M | 319.59M | 450.31M | 218.77M | 169.24M | 159.60M | 194.53M | 192.35M | 192.80M | 162.43M | 106.40M | 85.94M | 32.94M | 95.62M | 74.78M | 78.00M | 84.53M |
| EBITDA Ratio | 16.60% | 15.26% | 14.39% | 18.72% | 10.93% | 9.29% | 10.39% | 10.44% | 10.48% | 11.61% | 10.74% | 9.30% | 7.25% | 4.34% | 11.20% | 12.99% | 11.50% | 14.67% |
| Operating Income | 249.25M | 152.19M | 159.87M | 338.04M | 126.66M | 78.40M | 79.74M | 136.85M | 151.57M | 151.33M | 134.81M | 84.49M | 58.78M | 9.50M | 73.88M | 60.77M | 60.19M | 69.83M |
| Operating Income Ratio | 9.61% | 6.79% | 7.34% | 14.13% | 6.33% | 4.31% | 5.18% | 7.40% | 8.24% | 8.73% | 8.91% | 7.35% | 4.96% | 1.24% | 8.65% | 10.56% | 8.87% | 12.12% |
| Total Other Income/Expenses | 90.28M | 113.53M | 101.89M | 69.00M | 45.57M | 48.35M | 40.41M | 21.92M | 24.96M | 9.07M | 4.46M | 6.24M | -4.17M | -362.69K | -5.47M | -5.32M | -1.83M | -584.30K |
| Income Before Tax | 339.53M | 265.73M | 261.76M | 407.04M | 172.89M | 126.75M | 120.15M | 158.77M | 161.01M | 156.35M | 139.26M | 84.49M | 54.61M | 4.48M | 68.41M | 55.45M | 58.36M | 69.25M |
| Income Before Tax Ratio | 13.10% | 11.85% | 12.02% | 17.01% | 8.64% | 6.97% | 7.80% | 8.59% | 8.76% | 9.02% | 9.21% | 7.35% | 4.61% | 0.59% | 8.01% | 9.63% | 8.60% | 12.02% |
| Income Tax Expense | 86.39M | 65.02M | 63.86M | 115.32M | 30.36M | 15.85M | 33.68M | 53.43M | 57.45M | 58.78M | 46.10M | 27.93M | 19.55M | 2.44M | 24.27M | 29.01M | 22.50M | 28.47M |
| Net Income | 253.14M | 200.71M | 197.90M | 291.72M | 142.53M | 110.90M | 86.47M | 105.34M | 103.56M | 97.57M | 93.17M | 56.56M | 35.06M | 2.04M | 44.13M | 26.44M | 35.86M | 40.77M |
| Net Income Ratio | 9.76% | 8.95% | 9.09% | 12.19% | 7.12% | 6.09% | 5.61% | 5.70% | 5.63% | 5.63% | 6.16% | 4.92% | 2.96% | 0.27% | 5.17% | 4.59% | 5.29% | 7.07% |
| EPS | 0.34 | 0.22 | 0.24 | 0.37 | 0.18 | 0.14 | 0.12 | 0.13 | 0.13 | 0.13 | 0.12 | 0.07 | 0.04 | 0.00 | 0.15 | 0.12 | 0.17 | 0.20 |
| EPS Diluted | 0.34 | 0.22 | 0.23 | 0.37 | 0.18 | 0.14 | 0.12 | 0.13 | 0.13 | 0.13 | 0.12 | 0.07 | 0.04 | 0.00 | 0.15 | 0.12 | 0.16 | 0.20 |
| Weighted Avg Shares Out | 744.54M | 928.53M | 816.85M | 789.95M | 780.65M | 780.65M | 720.60M | 780.65M | 780.65M | 780.65M | 559.14M | 780.65M | 780.65M | 780.65M | 298.44M | 217.88M | 207.11M | 201.62M |
| Weighted Avg Shares Out (Dil) | 744.54M | 928.53M | 873.16M | 789.95M | 780.65M | 792.15M | 720.60M | 819.38M | 780.65M | 780.65M | 559.14M | 780.65M | 780.65M | 780.65M | 298.44M | 229.25M | 207.11M | 201.62M |
Source: https://incomestatements.info
Category: Stock Reports